Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:

A Phase Ib/II, Open-label Study of LJM716 in Combination With BYL719 Compared to Taxane or Irinotecan in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01822613
• Other study ID #: CLJM716X2103
• Status: Completed
• Phase: Phase 1
• Start date: July 26, 2013
• Est. completion date: June 3, 2016

Study information

• Verified date: May 2017
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.

Description:

The study design included a Phase 1b dose escalation portion to define the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) for the combination of LJM716 and alpelisib, followed by an open-label, randomized Phase 2 part to compare anti-tumor activity of LJM716-alpelisib combination versus physician's choice of second-line therapy (paclitaxel, docetaxel, irinotecan). However, the phase 2 part was not conducted as the study was terminated early due to limited anti-tumor activity with LJM716-alpelisib combination observed in phase 1b.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: June 3, 2016
• Est. primary completion date: June 3, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed esophageal squamous cell carcinoma (ESCC)

• No more than one prior chemotherapy regimen for recurrent or metastatic ESCC (for Phase II only).

• Progression during or after platinum-based therapy for recurrent or metastatic ESCC, or recurrence within 6 months of platinum-based chemotherapy or chemoradiotherapy for localized disease.

Exclusion Criteria:

• Patients who received prior phosphoinositide-3-kinase (PI3K) inhibitor or anti-receptor tyrosine-protein kinase erbB-3 (ERBB3 or HER3) antibody treatment, including bi-specific antibodies with HER3 as one of the targets (patients with prior exposure to pertuzumab or epidermal growth factor receptor (EGFR)-targeted agents are eligible)

• Patients who do not have an archival or fresh tumor sample (or sections of it) available or readily obtainable.

• Patients with central nervous system (CNS) metastatic involvement.

• Patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior to starting study treatment.

• Patients who have received definitive radiotherapy = 4 weeks prior to starting study drug, who have not recovered from side effects of such therapy and/or from whom = 30% of the bone marrow was irradiated.

• Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Intervention

Drug:
• LJM716
LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
• BYL719
BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
• Paclitaxel
In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
• Docetaxel
In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
• Irinotecan
In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label

Locations

Country	Name	City	State
Belgium	Novartis Investigative Site	Bruxelles
Canada	Novartis Investigative Site	Toronto	Ontario
Hong Kong	Novartis Investigative Site	Hong Kong
Korea, Republic of	Novartis Investigative Site	Seoul	Korea
Korea, Republic of	Novartis Investigative Site	Seoul	Korea
Singapore	Novartis Investigative Site	Singapore
Spain	Novartis Investigative Site	Barcelona	Catalunya
Taiwan	Novartis Investigative Site	Tainan	Taiwan ROC
Taiwan	Novartis Investigative Site	Taipei
United Kingdom	Novartis Investigative Site	Manchester
United States	University of Chicago Medical Center Dept of Onc	Chicago	Illinois
United States	Karmanos Cancer Institute Dept of Onc	Detroit	Michigan
United States	University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Hong Kong,  Korea, Republic of,  Singapore,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase Ib primary outcome measure: Incidence rate of dose limiting toxicities (DLTs).	The open-label dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or Recommended Phase II Dose (s) guided by the safety (incidence of dose limiting toxicities), efficacy, pharmacokinetics and pharmacodynamics data.	approximately 8 months
Primary	Phase II primary outcome measure: Progression free survival (PFS)	Progression-free survival is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate assessment.	Every 6 weeks from the date of the baseline computed-tomography (CT) scan until the date of first documented evidence of disease progression or date of death, whichever comes first, assessed up to 24 months.
Secondary	Safety and tolerability of the LJM716-BYL719	This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.	Every 21 days from the date of the baseline visit until the end of study visit (about 5 months)
Secondary	Best overall response (BOR), per RECIST 1.1 (Ph 1b )	BOR will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.	Every 21 days from the date of baseline computed tomography (CT) scan until end of treatment visit (about 4 months)
Secondary	Plasma concentration versus time profiles Plasma PK parameters of LJM716, BYL719	Plasma concentration versus time profiles Plasma PK parameters will be used to characterize the PK profiles of LJM716 and BYL719 when used in combination	Baseline, 2hr,4hr,8hr,24hr,48hr,96hr, 168 hr, every 21 days for 10 cycles (21 days each) and at end of treatment (about 4 months)
Secondary	Overall response rate (ORR) per RECIST 1.1 (Ph 1b )	Overall response rate will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.	Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Secondary	Duration of response (DOR) per RECIST 1.1 (Ph 1b )	Duration of response will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.	Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Secondary	Disease control rate (DCR) per RECIST 1.1 (Ph 1b )	Disease control rate will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.	Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Secondary	Overall survival (OS) per RECIST 1.1 (for Ph 1b )	Overall survival will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.	Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Secondary	Progression free survival (PFS) per RECIST 1.1 (Ph 1b )	Progression free survival will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.	Every 21 days from the date of the baseline computed tomography (CT) scan until the end of study visit (about 5 months)

External Links

•   Results for CLJM716X2103 from the Novartis Clinical Trials website